SCHEMBL2740948

SCHEMBL2740948

O=[N+]([O-])c1ccc(N/N=C/c2ccc(Br)cc2)c(S(=O)(=O)Nc2ccccc2Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.55
▸ PSMD14 O00487 2/20 0.55
▸ ALPL P05186 1/20 0.55
▸ ALPI P09923 1/20 0.55
▸ ALPG P10696 1/20 0.55
▸ MEN1 O00255 9/20 0.54
▸ KMT2A Q03164 9/20 0.54
▸ HTT P42858 5/20 0.54
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ NPC1 O15118 4/20 0.54
▸ RAB9A P51151 4/20 0.54
▸ MAPT P10636 11/20 0.51
▸ GAA P10253 5/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ XBP1 P17861 1/20 0.50
▸ ALDH1A1 P00352 4/20 0.49
▸ TNNI3 P19429 1/20 0.49
▸ TNNT2 P45379 1/20 0.49
▸ TNNC1 P63316 1/20 0.49
▸ GLA P06280 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2740990 0.90 L3MBTL1 (0.57) L3MBTL1PSMD14ALPLALPIALPG
SCHEMBL2740986 0.89 MEN1 (0.56) L3MBTL1PSMD14ALPLALPIALPG
SCHEMBL2741006 0.88 MEN1 (0.55) L3MBTL1PSMD14ALPLALPIALPG
SCHEMBL2741007 0.87 MEN1 (0.58) L3MBTL1PSMD14ALPLALPIALPG
SCHEMBL2740976 0.87 PSMD14 (0.53) L3MBTL1PSMD14ALPLALPIALPG
SCHEMBL2740994 0.86 L3MBTL1 (0.59) L3MBTL1PSMD14ALPLALPIALPG
SCHEMBL2740972 0.84 MAPT (0.58) L3MBTL1PSMD14ALPLALPIALPG
SCHEMBL2740985 0.84 MEN1 (0.54) L3MBTL1PSMD14ALPLALPIALPG
SCHEMBL2741014 0.83 MEN1 (0.54) L3MBTL1PSMD14ALPLALPIALPG
SCHEMBL2740975 0.83 MEN1 (0.51) L3MBTL1PSMD14ALPLALPIALPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-8088772-B2 Sulfonamides and their use as a medicament THE GENETICS COMPANY, INC. (CH) 2012-01-03 — — US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT BCOR, CBR3, SULT1E1 L3MBTL1 1642/4885PSMD14 2869/4885ALPL 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback